This company has been marked as potentially delisted and may not be actively trading. NASDAQ:PTI Proteostasis Therapeutics (PTI) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Proteostasis Therapeutics Stock (NASDAQ:PTI) 30 days 90 days 365 days Advanced Chart Get PTI alerts:Sign Up Key Stats Today's Range N/A50-Day Range$1.00▼$22.4252-Week Range N/AVolume9,405 shsAverage Volume1.04 million shsMarket Capitalization$37.57 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat cystic fibrosis. The company's lead product candidates for the treatment of CF include PTI-801, a cystic fibrosis transmembrane conductance regulator (CFTR) corrector agent; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. It has collaboration agreements with Cystic Fibrosis Foundation, Inc. to research, develop, and commercialize products for the treatment of CF, non-classical CF, and other pulmonary diseases in the United States or the European Union; and Genentech, Inc. for licensing the technology and materials relating to therapeutic small molecule modulators. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Boston, Massachusetts. Read More Receive PTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Proteostasis Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PTI Stock News HeadlinesUnlocking proteostasis: A new frontier in the fight against neurodegenerative diseases like Alzheimer'sJanuary 3, 2025 | msn.comHarness Therapeutics Appoints Seasoned Biopharmaceutical Leader, Ms. Meenu Chhabra Karson, as Board ChairApril 24, 2024 | globenewswire.comTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now. | Porter & Company (Ad)Greensboro joins incentive offers for $55M Honda expansion at PTI; Guilford County up nextJuly 20, 2023 | bizjournals.comFederal Police Summons India Minister in Bribery Probe, PTI SaysMarch 13, 2023 | bloomberg.com7 years later, probation and PTI for pair in North Bergen low-show/no-show job schemeOctober 6, 2022 | nj.comNImplied Volatility Surging for Proteostasis Therapeutics (PTI) Stock OptionsOctober 26, 2021 | finance.yahoo.comSee More Headlines PTI Stock Analysis - Frequently Asked Questions How were Proteostasis Therapeutics' earnings last quarter? Proteostasis Therapeutics, Inc. (NASDAQ:PTI) announced its quarterly earnings results on Monday, November, 16th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.17) by $0.01. When did Proteostasis Therapeutics IPO? Proteostasis Therapeutics (PTI) raised $51 million in an initial public offering (IPO) on Thursday, February 11th 2016. The company issued 3,900,000 shares at a price of $12.00-$14.00 per share. Leerink Partners and RBC Capital Markets served as the underwriters for the IPO and Baird and H.C. Wainwright & Co. were co-managers. What other stocks do shareholders of Proteostasis Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Proteostasis Therapeutics investors own include BHP Group (BHP), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Bristol Myers Squibb (BMY), Rite Aid (RAD) and Company Calendar Last Earnings11/16/2020Today8/24/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:PTI CIK1445283 Webwww.proteostasis.com Phone617-225-0096FaxN/AEmployees44Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$59.13 million Net MarginsN/A Pretax MarginN/A Return on Equity-75.39% Return on Assets-55.04% Debt Debt-to-Equity RatioN/A Current Ratio6.69 Quick Ratio6.69 Sales & Book Value Annual Sales$5 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$1.22 per share Price / BookN/AMiscellaneous Outstanding Shares52,185,000Free FloatN/AMarket Cap$37.57 million OptionableNot Optionable Beta1.16 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:PTI) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersNations are at war over what’s in this boxA resource known as Element 29 is quickly becoming one of the most sought-after materials on the planet. Goldm...Behind the Markets | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Proteostasis Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Proteostasis Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.